Arthur W. Yan, Derrick E. Fouts, Johannes Brandl, Peter Stärkel, Manolito Torralba, Eckart Schott, Hide Tsukamoto, Karen E. Nelson, David A. Brenner, Bernd Schnabl – 30 September 2010 – The translocation of bacteria and bacterial products into the circulation contributes to alcoholic liver disease. Intestinal bacterial overgrowth is common in patients with alcoholic liver disease. The aims of our study were to investigate bacterial translocation, changes in the enteric microbiome, and its regulation by mucosal antimicrobial proteins in alcoholic liver disease.

Peter Jepsen, Peter Ott, Per Kragh Andersen, Henrik Toft Sørensen, Hendrik Vilstrup – 30 September 2010

Peter J. Lewindon, Ross W. Shepherd, Meagan J. Walsh, Ristan M. Greer, Richard Williamson, Tamara N. Pereira, Kieran Frawley, Scott C. Bell, Jeffery L. Smith, Grant A. Ramm – 30 September 2010 – Cystic fibrosis liver disease (CFLD), which results from progressive hepatobiliary fibrosis, is an important cause of morbidity and mortality, but it is difficult to identify before portal hypertension (PHT) ensues.

Krishna Banaudha, Michael Kaliszewski, Tamara Korolnek, Liliana Florea, Man Lung Yeung, Kuan‐Teh Jeang, Ajit Kumar – 30 September 2010 – MicroRNAs (miRNAs) are approximately 22‐nucleotide noncoding RNAs that constitute silencers of target gene expression. Aberrant expression of miRNA has been linked to a variety of cancers, including hepatocellular carcinoma (HCC). Hepatitis C virus (HCV) infection is considered a major cause of chronic liver disease and HCC, although the mechanism of virus infection–associated hepatocarcinogenesis remains unclear.

Stella M. Martínez, Gonzalo Crespo, Miquel Navasa, Xavier Forns – 30 September 2010 – Liver biopsy has long been an important tool for assessing the degree of liver fibrosis. Information on the presence and degree of liver fibrosis is useful before making therapeutic decisions or predicting disease outcomes. The need to stage liver fibrosis, however, should decrease as treatment options become more successful (as has occurred with viral hepatitis).

Felix Stickel, Stephan Buch, Katharina Lau, Henriette Meyer zu Schwabedissen, Thomas Berg, Monika Ridinger, Marcella Rietschel, Clemens Schafmayer, Felix Braun, Holger Hinrichsen, Rainer Günther, Alexander Arlt, Marcus Seeger, Sebastian Müller, Helmut Karl Seitz, Michael Soyka, Markus Lerch, Frank Lammert, Christoph Sarrazin, Ralf Kubitz, Dieter Häussinger, Claus Hellerbrand, Dieter Bröring, Stefan Schreiber, Falk Kiefer, Rainer Spanagel, Karl Mann, Christian Datz, Michael Krawczak, Norbert Wodarz, Henry Völzke, Jochen Hampe – 30 September 2010 – A recent genome‐wide study revealed an assoc

Christer Baeck, Konrad Streetz – 28 September 2010

Yann Malato, Holger Willenbring – 28 September 2010

Nazia Selzner, David R. Grant, Itay Shalev, Gary A. Levy – 28 September 2010 – Liver transplantation is now recognized as the treatment of choice for end‐stage liver failure. Its success can be attributed largely to the generation of selective immunosuppressive agents, which have resulted in a dramatic reduction in the incidence of acute rejection and improvements in the short‐ and long‐term outcomes of patients.

Doris Wagner, Daniela Kniepeiss, Florian Iberer, Astrid Fahrleitner‐Pammer, Peter Kornprat, Karlheinz Tscheliessnigg – 28 September 2010